Molecular machineries of pH dysregulation in tumor microenvironment: potential targets for cancer therapy

Mohammad Reza Asgharzadeh1,2, Jaleh Barar3,4, Mohammad M. Pourseif3, Morteza Eskandani3, Mojtaba Jafari Niya1,2, Mohammad Reza Mashayekhi5, Yadollah Omidi3,4*

1 Department of Biology, Fars Science and Research Branch, Islamic Azad University, Marvdasht, Iran
2 Department of Biology, Marvdasht Branch, Islamic Azad University, Marvdasht, Iran
3 Research Center for Pharmaceutical Nanotechnology, Biomedicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran
4 Department of Pharmaceutics, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran
5 Department of Genetic, Tabriz Branch, Islamic Azad University, Tabriz, Iran

Abstract

Introduction: Cancer is an intricate disorder/dysfunction of cells that can be defined as a genetic heterogeneity in human disease. Therefore, it is characterized by several adaptive complex hallmarks. Among them, the pH dysregulation appears as a symbol of aberrant functions within the tumor microenvironment (TME). In comparison with normal tissues, in the solid tumors, we face with an irregular acidification and alkalinization of the extracellular and intracellular fluids.

Methods: In this study, we comprehensively discussed the most recent reports on the hallmarks of solid tumors to provide deep insights upon the molecular machineries involved in the pH dysregulation of solid tumors and their impacts on the initiation and progression of cancer.

Results: The dysregulation of pH in solid tumors is fundamentally related to the Warburg effect and hypoxia, leading to expression of a number of molecular machineries, including: NHE1, H+-pump V-ATPase, CA-9, CA-12, MCT-1, GLUT-1. Activation of proton exchangers and transporters (PETs) gives rise to formation of TME. This condition favors the cancer cells to evade from the anoikis and apoptosis, granting them aggressive and metastasis phenotype, as well as resistance to chemotherapy and radiation therapy. This review aimed to discuss the key molecular changes of tumor cells in terms of bio-energetics and cancer metabolism in relation with pH dysregulation. During this phenomenon, the intra- and extracellular metabolites are altered and/or disrupted. Such molecular alterations provide molecular hallmarks for direct targeting of the PETs by potent relevant inhibitors in combination with conventional cancer therapies as ultimate therapy against solid tumors.

Conclusion: Taken all, along with other treatment strategies, targeting the key molecular machineries related to intra- and extracellular metabolisms within the TME is proposed as a novel strategy to inhibit or block PETs that are involved in the pH dysregulation of solid tumors.

Introduction

Solid tumors, as a class of complex diseases, are characterized by their unique hallmarks, including: anomalous initiation and development through altered genotype and phenotype, self-organization and adaptation, collective specific behavior with molecular networks and irregular pattern formation and dynamism within tumor microenvironment (TME). Such traits result in an uncontrolled process of cell growth, division, metastasis and progression.

The cancer cells, in comparison with normal cells, exhibit distinctive physiopathology, including: (a) autonomous mechanisms of cell growth, (b) divergence from the factors involved in growth inhibition, (c) evasion from anoikis,
immunosurveillance and apoptosis, (d) evolutionary regulation of growth, (e) invasiveness and metastatic colonization. These characteristics are manifested through genetic and epigenetic changes. The initiation of cancer is deemed to be linked with the hypoxia and irregular metabolism in energetic pathway, in particular glucose, resulting in production of acidic byproducts. Such dysregulation of pH within the cancer cells and TME, in comparison with the normal cells, seems to be one of the main causes for the metastasis, drug resistance, and the recurrence of the disease after the course(s) of treatment. The normal cells have intracellular pH (pH\textsubscript{i}) of ~ 7.2, but in cancer cells, it is about 7.4. Further, in the normal cells extracellular pH (pH\textsubscript{e}) is approximately 7.4, while in cancer cells it reduces to 6.7-7.1. Therefore, any changes in the activity and/or expression of membrane ion pumps and proton transfers may lead to a lower pH\textsubscript{i} and higher pH\textsubscript{e}. All these occur because the cancer cells can significantly increase the functional expression of several key molecular machineries, including: Na\textsuperscript+-H\textsuperscript{+} exchanger (NHE1), H\textsuperscript{+}-ATPases, carbonic anhydrase IX (CA IX) and carbonic anhydrase XII (CA XII).

Based on scientific praxis, a number of theories have been coined to explain the unique behavior of cancer cells. Some of studies have shown that the hypoxia, Warburg effect and aberrant metabolism play central roles in the pH dysregulation and also progression and metastasis of cancer cells. In 1880s, Steven Paget articulated the "seed and soil" notion. Based on this theory, environment (soil) is necessary for the tumor cells (seed). In this concept, however, there still remain some key questions. How exactly cancer cells can escape from the immune system and apoptosis? What are the main causes of their resistance to chemotherapy? In fact, answering all these questions can improve the missing link(s) between the actual mechanisms of cancer progression and pharmacotherapy strategies. The right answers to these questions may be entombed within the TME as a crucial part of the cancer puzzle. In this review, we will discuss the TME and its role in cancer development and the factors involved in the pH dysregulation. Further, the relationship between the pH dysregulation and some key molecular machineries such as NHE1, H\textsuperscript{+}-ATPases, CA9 and CA12 are articulated in terms of their association with invasion, metastasis, and drug resistance. At the end of each section, we will focus on some genetic changes that can be occurred in the TME on the molecular machineries such as NHE1, H\textsuperscript{+}-ATPases, CA9 and CA12.

Tumor microenvironment

Intricate interacting network between the cancerous and non-cancerous cells often lead to formation of a permissive milieu called tumor microenvironment. From pathological perspective, the TME include blood vessels, bone marrow-derived inflammatory cell, signaling molecules, extracellular matrix (ECM) and lymphocytes. As shown in Fig. 1, the cells involved with TME are recognized by various cell-specific molecular markers often expressed on the cell surface.

Based on scientific praxis, a number of theories have been coined to explain the unique behavior of cancer cells. Some of studies have shown that the hypoxia, Warburg effect and aberrant metabolism play central roles in the pH dysregulation and also progression and metastasis of cancer cells. In 1880s, Steven Paget articulated the "seed and soil" notion. Based on this theory, environment (soil) is necessary for the tumor cells (seed). In this concept, however, there still remain some key questions. How exactly cancer cells can escape from the immune system and apoptosis? What are the main causes of their resistance to chemotherapy? In fact, answering all these questions can improve the missing link(s) between the actual mechanisms of cancer progression and pharmacotherapy strategies. The right answers to these questions may be

Fig. 1. Schematic representation of tumor microenvironment. NK-cell: natural killer cell, CAF: cancer associated-fibroblast.
by induction of factors such as IL-8, NF-κB and VEGF/VEGF-A via HIF-1.\textsuperscript{15}

**Tumor microenvironment facilitates tumor invasion**

Metastasis of cancer cells is a complex process that is associated with key serial events, including: (i) epithelial–mesenchymal transition (EMT), (ii) excitation of angiogenesis, (iii) invasion of cancer cells from the basal membrane into the lymphatic or blood vessel, (iv) extravasation of cancer cells from the blood or lymphatic vessel, and finally (v) formation of new growing colonies in a far-away site.\textsuperscript{1}

Inflammation appears to be a main factor in tumorigenesis. Surprisingly, the markers inflammatory mediators that promote cancer development are cancer fighting T cells, DCs, macrophages, natural killer (NK) cells and tumor-infiltrating cells.\textsuperscript{6,16,17} Previous studies have shown that the high level of cytokines such as interleukins (ILs), in particular II-1, II-6 and II-8, are correlated with tumor progression, invasion, mobility and metastasis. Tumor-infiltrated immune cells produce several cytokines in favor of MET, including: TGF-β, TNF-α and II-1B.\textsuperscript{18} Cancer-associated fibroblasts (CAFs) are part of TME, that is the cause of tumor progression through production of II-6.\textsuperscript{19} Several cell survival signaling pathways mediated through II-6 have so far been identified. Some of these pathways include PI3K/AKT, Ras/Raf/MEK-ERK1/2, JAK/STAT3, SHP2/RAFTK, and Src-family tyrosine kinase pathways.\textsuperscript{20} Further, the TME is composed of various types of cells whose interactions with TGF-β appear to be diverse. This complex environment is created during cancer initiation, progression and metastasis within the TME. The TGF-β can inhibit the angiogenesis in the early-stage of cancer, but not very effective at the cancer progression stages. Efficiency of TGF-β based responses is highly dependent on the cell type and potential genetic changes on the TGF-β receptors and/or ligands. The TGF-β signaling pathways are related to activation of downstream targets such as TAK1, MAPK, Ras, Rho A, PP2A and SMAD.\textsuperscript{21} It has been found that the TNF-α, not only involved in the MET induction in cancer cells, but also associated with an invasive phenotype of mammary epithelial cells and finally cancer metastasis. In the epithelial cells, TNF-α binds to its receptor with high efficiency. This connection can activate NF-κB transcription factor, and subsequently regulates the expression of some genes involved in MET and invasion. The NF-κB indirectly affects the Snail-like proteins. These proteins act as a key inhibitor in E-cadherin transcription. Besides, the NF-κB increases the expression of hepatocyte growth factor (HGF) ligand/receptor. The HGF secrets from the primary mesenchymal cells, such as cancer associated fibroblasts, and it is involved in planning and regulating cancer cell invasive growth.\textsuperscript{22}

Metastatic cancer cells are the main cause of cancer death. These can simply occur during the pH dysregulation, and GTase CDC42 is one of the key requirements for the increase of pH. Although CDC42 activity is not dependent on the physiological pH changes, several guanine nucleotide exchange factors (GEFs), such as GEF Dbl’s Big Sister, are concerned in CDC42 motivation. These proteins are activated and released across the plasma membrane at pH over 7.2. Moreover, higher pH\textsubscript{i} and lower pH\textsubscript{c} act as an enhancer in invasion and metastasis via other mechanisms. For instance, due to the opening of aquaporin-type water channels, which can lead to amoeboid movement, the invadopodia is formed and then induce the protease activities that lead to degradation of ECM by enzymes such as matrix metalloproteinase.\textsuperscript{2} Recently Martin and colleagues mathematically predicted that the rate of tumor invasiveness does not increase consistently with pH\textsubscript{i} decrease. In this work, several parameters were considered such as the interaction between cancer cells, stromal cells, cell death and decomposition processes of ECM. This simulation model represented that the onset of the formation of acidic extracellular milieu, can initially increase the cell invasion and then lead to stromal cells death.\textsuperscript{23}

As reported previously, the pH dysregulation in TME induces a set of critical functions which can in return trigger progress and invasion of tumor cells. Warburg effect and aberrant glucose metabolism in cancer cells can result in production of protons and the other acidic metabolites that these conditions increase intracellular pH. After this change, the cancer cells use plasma membrane ionic pumps to maintain the intracellular pH. Such pH change is one of the main pathological characteristics of solid tumors that can lead to intracellular and extracellular fluids alkalinization and acidification, respectively.\textsuperscript{1} These changes can be considered from several aspects, including:

(i) pH changes that can modulate numerous protein regulating complex cell functions,
(ii) despite existence of several proteins involved in such phenomena, only a limited number of these proteins could only be used as a pH sensor. Therefore, regulatory proteins are selected based on the physiological changes in pH\textsubscript{i} and pH\textsubscript{c}, and
(iii) the pH dysregulation, along with the other regulatory mechanisms, can be effectively involved in post-translational protein modifications.\textsuperscript{2}

An increase in the pH\textsubscript{i} can result in induction of positive signals for cellular proliferation, and promotion of cellular survival by controlling apoptosis. Cell proliferation is associated with several pH-dependent mechanisms. Intracellular pH higher than 7.2 can stimulate growth factors and transit the cell cycle toward the S phase. This seems to be the main cause for progression of the cell cycle through G2/M phase. In contrast, pH\textsubscript{i} lower than 7.2 can transit the cells into the G2/M phase by the cyclin-dependent kinase 1-cyclin B. Therefore, pH-dependent regulating activity of CDK1-cyclin B could be a conservative mechanism for entering cellular division into the mitosis and meiosis.\textsuperscript{24,25} It should be stated that the acidic pH imposes important structural changes in the pro-apoptotic protein BAX to improve its insertion into
the peripheral mitochondrial membrane to make the holes that can enhance the membrane permeability and releases cytochrome-c and various pro-apoptotic proteins into the cytosol. Hereafter, activation of caspase by cytochrome-c in the cytosol is more efficient at a pH of about 6.8.54

Tumor hypoxia is important for TME, because the tumor-associated macrophages (TAMs) are part of the TME accumulation in the necrosis and hypoxia segments. As a result, it releases hypoxia-induced chemo-attractants such as endothelin(s), endothelial monocyte activating polypeptide II (EMAP2) and vascular endothelial growth factor (VEGF). TAMs contribute to the migration, invasion and metastasis of malignant cells, in large part through ILs such as IL-10 low and IL-12. Further, adipocytes within the TME provide fatty acids as a fuel source for the cancer cells, and as a result contribute to metastasis.14

It should be also noted that the non-cellular parts of TME play important regulatory roles in the progression of cancer. These parts include biomolecules involved in the formation of ECM as well as physical and chemical parameters such as oxygen tension, pH, interstitial pressure, and fluid flux.26,27 The ECM density is an important factor in tumor cells aggressive phenotype. For example, the density of the breast cancer tissue is associated with the phenotype of cancer more than 30%, while BCR1 and BCR2 mutations have only a 5% role in the breast cancer.28,29

An increase in tissue stiffness appears to enhance cancer development through altering focal adhesions, integrin signaling, Rho/Rho-associated protein kinase (ROCK) pathway activation, and actomyosin- and cytoskeletal-dependent cell contractility.30 Within the TME, all cellular secretions can be considered as non-cellular entities. The ECM-related biomolecules (e.g., collagens, elastin, proteoglycans, hyaluronan, glycoproteins), degrading enzyme and soluble factors (e.g., cytokines, growth factor and chemokines) are involved in the formation of TME.31,32

It seems that the overexpression of ECM-degrading enzymes such as matrix metalloproteinases (MMPs) can increase the tumorigenesis. For example, in ovarian cancer, MMP-2 and MMP-9 have been shown to associate with cancer metastasis.33,34 In addition to MMPs, other ECM proteins, such as "a disintegrin and metalloproteinase" (ADAM), are important in the development of tumors. Of these proteins, ADAM with thrombospondin motifs (ADAMTS) were shown to be involved in the remodeling of ECM in tumourigenesis.35-37 Further, the lysyl oxidase (LOX) enzymes and transglutaminases are main molecules in tumor progression.38,39

Integrins are cell membrane adhesion molecules that are highly contributed in the development of tumors. For example, in prostate cancer, the overexpression of metastatic αvβ6 integrin was shown to upregulate MMP-2, which in return can promote cancer cell-mediated program of osteolysis through degradation of matrix.40 Studies have shown that hyaluronan plays an imperative role in the development of various types of cancers, such as prostate, breast and ovarian cancers. This biomolecule, by activating CD44 and RHAMM (receptor for hyaluronan-mediated motility), was shown to mediate some important signaling pathways to favor the cancer progression, including: NFkB and mitogen-activated protein kinase (MAPK) pathways.41-43 A group of ECM-related biomolecules, so-called matricellular proteins, were shown to contribute to the modulation of ECM, including: tenasin C (TN-C), SPARC (secreted pro-protein, acidic and rich in cysteine), thrombospondin-1 and−2 and osteopontin.44,45 Although these biomolecules do not directly involved in the formation of cell construction substances, they often participate in modulation of cell-matrix interactions. Of these, TN-C was shown to play a key role in invasiveness of tumor cells.46 Now, in fact, there exist compelling evidence upon specific interactions between ECM molecules and cancer cells within the TME in service or disservice of cancer progression.47,48

**Drug resistance related to TME**

Emergence of resistance to chemotherapy by cancer cells is major issue in clinical oncology, resulting in failure of treatment and possible relapse of disease. Various factors are involved in attaining such resistance against chemotherapy, immunotherapy and radiotherapy, including: epigenetic changes, genetic mutations, aberrant functions within TME, structural components of the stroma, the inter- and/or cross-communication of cancer cells with each other and other elements of TME, hypoxia condition and tumor cells pH.49-54

The interaction between tumor cells and their microenvironement is very important in emergence of drug-resistance. It has been shown that insulin-like growth factor I (IGF-I) protects colon cancer cells against several cytotoxic factors.55 The apoptotic response in small-cell lung cancer chemotheraphy was shown by the inhibition of integrins through detrimental impacts on DNA.52 Under hypoxia tumor condition, hypoxia-inducible factors (HIFs) as a transcription factor was shown to elicit the expression of several genes involved in the survival and angiogenesis of solid tumors.53,56 Tumor hypoxia conditions can also disrupt the protein foldings in the endoplasmic reticulum,57 which may favor cancer cells in attaining drug-resistance by targeting elements such astoposomerase II.58 The traits of TME such as irregularly non-integrated tumor microvasculature, highly pressurized tumor interstitial fluid, and dysregulated pH appear to be involved in drug-resistance properties of cancer cells.1,59,60 In fact, the penetration and absorption of anticancer drugs (e.g., vinblastine, doxorubicin, vincristine, mitoxantrone, paclitaxel) were shown to be altered in the acidic TME.61,62

TME-mediated resistance can be initiated by several cells and some key structural components of the stroma, which are not limited to endothelia, fibroblasts, pericytes, neutrophils, macrophages, integrin and collagen.53,64 Moreover, there exist several other extracellular factors that are involved in drug resistance, including: cytokines, proteases and growth factors.53,65 While the drug resistance in cancer cells is regulated by various mechanisms, this phenomenon may increase the EMT as a direct effect.
through an array of molecules derived from TME. This mechanism occurs by activation of intracellular networks linked with epidermal growth factor (EGF)/EGF receptor (EGFR), hepatocyte growth factor/c-met, Wnt/beta-catenin axes and multiple cytokine/chemokine-mediated pathways.67-69

Besides, solid tumors possess different strategies to utilize cancer stem cells (CSCs) and mesenchymal stem cells (MSCs). For example, breast tumors release monocyte chemotactic protein-1 and prostate tumors secrete CXCL16.70,71 Likewise, MSCs can release polyunsaturated fatty acids, 12-oxo-5,8,10-heptadecatrienoic acid and hexadeca-4,7,10,13-tetraenoic acid which stimulate the resistance to many chemotherapeutic agents.72 Recently, studies have shown that cancer-associated fibroblasts (CAFs) are able to secrete the collagen type-2, and hence reduce the absorption of chemotherapy, resulting in inevitable drug resistance.73

Genetic and epigenetic changes in TME
To date, some de novo information has been obtained by genomics, epigenetics, transcriptomics, proteomics and metabolomics, which can be used in our combat against initiation and development of solid tumors.74 DNA methylation is a chemical modification in the structure of DNA that can lead to chromatin structural remodeling/transformation, gene availability and expression. In mammals, DNA methylation happens at 70% of cytosine-guanine (CpG) rich regions. Recently, it has been found that DNA methylation profile may involve with initiation of the TME and progression of cancer. DNA methylation can influence the performance of different areas of the DNA such as promoter, silencer, enhancer and non-coding RNAs. Bisulfite sequencing and methyl-CpG-binding domain (MBD, or MethylCap-Seq) can be used to identify the methylated areas of DNA. Several studies have shown that, in the breast cancer, the promoter of some key genes are hypomethylated, including: insulin-like growth factor (IGF), multidrug resistance (MDR1) and metastasis promoting protease genes. By contrast, genes prompters involved in the DNA repair, apoptosis, metastasis, control of proliferation and angiogenesis are hypermethylated in cancer. For example, cyclin-dependent kinase inhibitor 2A (p16), O6-methylguanine DNA methyltransferase (MGMT), MutL homolog 1 (MLH1), retinoic acid receptor beta (RAR-β), Ras association domain-containing protein 1(RASSF1A) and phosphatase and tensin homolog (PTEN) epitomize these elements.75 Histone modifications and DNA methylation have been observed in CAFs in various types of cancers, including gastric and pancreatic cancer. It has been found that CYP19 and CXorf12 genes are hypermethylated in breast adipose fibroblasts (BAFs) and CAFs, respectively. Histone H3K27 methylation in breast cancer is associated with aggressive phenotype.18

Alteration in microRNAs in TME
Micro RNAs are considered as biomarkers of different cancer types. New studies indicated that miRNAs influence the metastasis phenomena, in large part through interactions with different elements of TME. Especially, miR-210 is secreted by metastatic breast cancer cells and transferred to epithelial cells which lead to increase in cells migration and angiogenesis. The miRNAs can be transmitted between cells. For example, miR-223 released by TAMs are activated by IL-4 and transferred to the breast cancer cells, which are able to promote the tumor invasion and metastasis. The transmission mechanisms of miRNAs between cell types seems to be one of the mechanisms involved in metastasis within TME.76 In the breast cancer, the miR-21 is overexpressed, resulting in upregulation of TGF-β. While the upregulation of miR-31 in the CAFs breast cancer disturbs the ability of CAFs to stimulate the cancer cell invasion and migration, the downregulation of miR-15 and miR-16 in prostate cancer CAFs lead to an enhanced tumor growth and progression. This latter effect seems to be mediated by reduced post-transcriptional modification of Fgf-2, resulting in promotion of metastasis.19 Thus, microRNAs are considered as small non-coding RNA molecules that can control the inhibition or progression of cancer as well as many other pathogenic diseases. Of these systems, TGF-β interacts with SMADs, and hence, mutations and deletions in these areas are important in cancer. In prostate and colon cancer, 18q21 gene locus which encode SMADs 2 and 4 are most often mutated or deleted. SMAD4 mutations are rare, but can be found in breast cancer. Further, SMAD2 mutation has been recognized in lung, colon and head and neck cancer. Lack of SMAD3 expression in choriocarcinoma cells is associated with the downregulation of tissue inhibitor of metalloproteinases (TIMP-1), which may increase the activity of protein metalloproteinase - important for tumor invasion.20

**Na⁺/H⁺ exchanger 1 (NHE1)**
The pH change in the cancerous cells, in comparison with the normal tissue, seems to be common in most solid tumors. In fact, they show some similar phenotypic properties in terms of pH dysregulation, which includes some common key metabolic changes. Such alterations seem (i) to promote acid-producing pathways, (ii) to activate the oncogenic signals, (iii) to induce and develop the hypoxia, and (iv) to alter the functional expression of some key molecular transporters involved in the regulation of pH. Despite these changes, most of studies have focused on the clinical importance of proton transporters, in particular NHE1 and V-ATPase. Factors that promote the cellular pH or enhance the functional expression of NHE1 leading to an increased pH and carcinogenicity include viruses (e.g., human papilloma virus), persistent hypoxia and HIF, oncogenes and viral proteins, p53 defect, growth factors, hormones, and chemicals carcinogenic and genomic products.77

**Structure and function of NHE1**
Changes in the functional expression of plasma membrane
It is believed that NHE1 performs a variety of functions in mammalian physiology. NHE1 exists abundantly in various types of cells, which is found as an extended member. Although it is placed on the cell surface, its functional presences at different domains in various cell types reflects its diverse functions. For example, NHE1 in fibroblasts is localized at the boundary of lamellipodia, the basolateral membrane of epithelia, and the disks and t-tubules of cardiac. Further, it should be noted that the tissue distribution and intracellular position of NHEs vary markedly. Recent studies have identified a variety of plasma membrane NHEs and several organelle-based isoforms with similar functions in mammalian physiology. NHE1 exists in many specialized secretive cell types, for example the acinar cells of the parotid and sublingual glands, the activation of NHE1 is also necessary for the secretion of derived fluids. Change in the activity of NHEs is related to the pathogenesis of several diseases, such as hypertension, congenital secretive diarrhea, diabetes, and tissue harm affected by ischemia/reperfusion.

The phosphorylation alteration of basic amino acids in C-terminal and the reaction with intracellular lipids and proteins can regulate the NHE1 activities (Fig. 3). The approximate binding sites of regulatory proteins and cofactors which bind to NHE1 in breast cancer cells are shown in Table 1. A number of protein kinases are involved in the regulation of NHE1, protein kinase p160ROCK facilitates the assembly of actin stress fibers through RhoA which leads to the activation of fibroblastic NHE1. Angiotensin II stimulates the NHE1 through ERK phosphorylation, which depends on p38MAPK. Therefore, the phosphorylation of NHE1 at residues T718, S221, S286, and S297 seem to regulate the apoptosis as reported previously for the pro-B cells. Protein kinase B (Akt) plays a key role in phosphorylation of S473, and inhibits the activity of NHE1 in myocardial cells, perhaps by

ionic pumps and also transmitters which facilitates the distribution of H+ in the extracellular fluid may result in stabilized increased the pH, and decreases the pH. One of the plasma membrane ionic pumps with enhanced functional expression is NHE1. The human NHE1 gene is a member of a gene family that is also called solute carrier 9 (SLC9). The NHE gene family is pH regulator of the cytoplasm and intracellular organelles. There are 9 different genes locus (NHE1-9 or /SLC9A1-9) in the human genome for the NHE gene family while some related pseudogenes have also been identified in human genome. These genes encode proteins that have 25 to 75% similarity with each other. The human NHE1 (Fig. 2) is an integral membrane protein and encoded by SLC9A1 gene, which is composed of 815 amino acids, and comprises two domains:

- (i) a hydrophobic N-terminal membrane domain which contains amino acids 1 to 500 and show a secondary structure with 12 transmembrane spans, to which the NHE1 transport activity is attributed, and
- (ii) a domain embracing 501 to 815 amino acids constituting the cytoplasmic domain (C-terminus tail) that is fundamental for the NHE1 regulation.

The N-terminal domain of NHE1 exchanges intracellular H+ with extracellular Na+. This molecular exchanger protects cells from the acidification and regulates pH. Moreover, human NHE1 is involved in some important biological and physiological activities of cells, including: regulation of intracellular pH, acid-base electrolyte control, homeostasis, adhesion, migration and proliferation. Studies have shown that early stage transformation by oncogene(s) in normal cells occurs along with NHE1 activity, and then the cytosolic alkalization happens in consistent correlation with the occurrence of glycosylation. In addition, it has been shown that such alkalization stimulates a set of transformation markers such as an increase in the growth rate, substrate-independent growth, and growth factor(s)-independent growth.

The intracellular pH determines that how cells obtain their energy, in which an alkalinized pH stimulates an anaerobic glycolysis, while an acidic pH provokes an oxidative phosphorylation process. Such molecular storms caused by the activation of NHE1 decrease with its inhibition leading to suppression of tumor progression, in large part by acidifying the intracellular fluid of cancer cells.

Further, it should be noted that the tissue distribution and intracellular position of NHEs vary markedly. Recent studies have identified a variety of plasma membrane NHEs and several organelle-based isoforms with similar functions in mammalian physiology. NHE1 exists abundantly in various types of cells, which is found as an extended member. Although it is placed on the cell surface, its functional presences at different domains in various cell types reflects its diverse functions. For example, NHE1 in fibroblasts is localized at the boundary of lamellipodia, the basolateral membrane of epithelia, and the disks and t-tubules of cardiac. It is believed that NHE1 performs two important functions. First, it is the chief alkalinizing mechanism in various types of cells to protect cells against the harmful effects of increased acidity. If the production of acidic metabolites increases, the H+-derived from the related metabolic pathways via different secretory routes are intensified and remain unchecked. Hence, to maintain the acid-base balance in the cytoplasm, it plays a central role along with bicarbonate-transporting systems such as, Na+-HCO3 co-transporters, Na+-dependent HCO3 /Cl exchangers and Cl /HCO3 exchangers. Second, it provides with extracellular Na+), which is paired with Cl /HCO3 in the extracellular fluid may result in a steady state level. As a result, the cytoplasmic contents is modulated by a sharp rise in extracellular osmolality. In many specialized secretive cell types, for example the acinar cells of the parotid and sublingual glands, the activation of NHE1 is also necessary for the secretion of derived fluids. Change in the activity of NHEs is related to the pathogenesis of several diseases, such as hypertension, congenital secretive diarrhea, diabetes, and tissue harm affected by ischemia/reperfusion.
Interfering with CaM binding. In other cell types, although Akt phosphorylation leads to the activation of NHE1, and plays a key role in the survival, growth, and perhaps metastasis. In the phosphorylation of NHE, some other protein kinases are involved through various mechanisms such as Ca2+/calmodulin-dependent kinase (CaMKII) and Nck-interacting kinase (NIK) mechanisms.4

Studies have shown that the activity of NHE1 in the breast cancer leads to acidification of extracellular microenvironment. This process facilitates the degradation ECM by protease and increases the invasion and metastasis.4 Fibroblast cells with mutated NHE1 show lower pH as compared to the NHE1 of wild type cells. In such circumstances, the expression of enzymes related to the glycogenesis reduces 3-4 times, which include fructose-1,6-bisphosphatase, galactokinase and phosphorylase kinase. Besides, the concentration of lactate dehydrogenase (LDH) is reduced, which is an enzyme crucial for the Warburg effect.1 There are several key inhibitors and protein kinases that justify the activity of NHE1. These regulators can be considered as interesting molecular target for pharmacotherapy of cancer, (e.g., ErbB2).96 The NHE1 has a critical role in chronic and acute myeloid leukemia differentiation.

Table 1. Summarizing NHE1 regulation by proteins, cofactors, and protein kinases

| Regulators                              | Mechanism of action                                                                 | Biding site(s) | Ref.       |
|----------------------------------------|-------------------------------------------------------------------------------------|----------------|-----------|
| Calmodulin (CaM)                       | Binding to a high- and low-affinity, blocks an auto-inhibitory site, consequently activating NHE1 | From AAs 636 to 700 | 79        |
| Calcineurin homologous protein (CHP)   | (i) CHP1: NHE1 activity and its stabilization and localization to the plasma membrane (ii) CHP2: overexpressed in tumor cells; it is protective against serum deprivation-induced cell death by enhancing pH and promoted proliferation of tumor cells (iii) CHP3: promote maturation and cell surface stability | 518 to 537 | 87-89, 90 |
| Phosphatidylinositol 4,5-biphosphate (PIP2) | Depletion of PIP2 results in ATP-dependent inhibition of NHE1 | 513, 520, 556 and 564 | 91        |
| Carbonic anhydrase II (CAII)           | Catalyzing the production of HCO3− and H+ from the hydration of CO2                | 790 to 802     | 92        |
| Actin-binding ERM                      | Proper localization of NHE1 to the plasma membrane and maintaining cell shape     | 552 and 560    | 93        |
| Heat shock protein 70 (Hsp70)          | Binding to NHE1 and possible play a role in protein folding                        | Unknown site   | 94        |
| 14–3–3 adaptor protein                 | Binding to NHE1 when it is phosphorylated at S703. Thereby NHE1 has activate by protecting S703 from dephosphorylation | 703            | 95        |
| Several protein kinases                | NHE1 stimulation and activation                                                   |                | 85        |
simultaneous pharmacological inhibition of P38 MAPK and NHE1 under hypoxia significantly suppresses the expression of C/EBP. These results show the hypoxia-induced K562 differentiation by inhibiting NHE1, in large part due to upregulation of C/EBPα through p38 MAPK signaling pathway. This suggests that the inhibition of NHE1 in hypoxic microenvironment could be considered as possible treatment for the leukaemic disease.

**NHE1 inhibitor compounds**

The progress and maintenance of converting pH gradient is directly caused by the ability of tumor cells in withdrawal of proton. Such proton emission depends on cell buffer size and is stimulated through the transporters and exchangers of the proton attached to the membrane, mainly by NHEs. This gene family has its specific inhibitors. The NHE gene family can be inhibited by various groups of pharmacological compounds, including: amiloride and its analogues, benzyolguanidinium-based formatives, cimetidine, clonidine and harmaline. It might be inhibited by imidazoline or guanidinium groups. The sensitivity of these compounds for NHEs are largely dependent upon the type of NHE, where NHE1 display the greatest sensitivity as compared to others with the following trend (NHE1≥NHE2>NHE5>NHE3>NHE4). Clinical inhibition of NHE1 with potent and much more selective inhibitors should be taken into consideration to attain highly selective and potential targeting in cancer therapy. For example, cariporide, compound 9 T, 2-aminophenoxazine-3-one (Phx-3) could be used.

The first inhibitor of NHE was amiloride, which was shown to decrease VEGF that is an activator of urokinase-type plasminogen (uPA), MMPs and other proteases. All these molecular machineries are in favor of activation of the metastasis. In recent years, many researchers have aimed to produce potent and specific compounds to inhibit the activity of NHEs. In this regard, potential amiloride analogues have been made, including: ethyisopropylamiloride (EIPA), hexamethylamiloride (HMA) and dimethylamiloride (DMA).

In addition to amiloride-based compounds, other compounds such as cariporide and eniporide have been used in several experiments to inhibit the activity of NHE1. These tests were not against cancer, but rather in the field of cardiological to ischaemic-reperfusion disservice. Finally, it has been shown that cariporide is beneficial to overcome drug resistance and metastasis process. Studies have shown that cariporide diminishes the hypoxia-dependent tumor invasion and migration in human tongue squamous cell carcinoma and Tca8113 cells by inhibiting NHE1. Also, pharmacological inhibition of p38 mitogen-activated protein kinase (MAPK) specifically inhibits the expression of C/EBPα under hypoxia conditions, of course, which happens after the inhibition of NHE1.

**The genetic variation and diversity**

The NHEs have been detected generally in organisms from prokaryotes to eukaryotes such as plants, fungi and animals. In prokaryotes like the *Escherichia coli*, there are two types of NHEs (NhaA and NhaB) that are employed in H⁺ gradient produced by H⁺-ATPase to export Na⁺ or Li⁺. In terms of stoichiometry, the NhaA and NhaB transported 1Na⁺:2H⁺ and 2Na⁺:3H⁺, respectively. Various eukaryotes encoding different types of NHEs, for example, *Arabidopsis thaliana* contains at least several NHE proteins so-called AtSOS1 or AtNHX1–6 and the nematode *Caenorhabditis elegans* encodes nine NHE-like proteins such as CeNHX1–9. Wakabayashi et al identified mutations of Tyr⁴⁵⁴ in *NHE1* sequence analysis in terms of probability variant(s). A and B) Some of main natural variants, C) Polymorphism at the position 682 lead to change from asparagine (N) to lysine (K). D) The 261-length domain that is missed in NHE1 isoform 2.
pH dysregulation in tumor microenvironment

The V0 complex is proton pumpers across the i

Even short-
i

102

162

78

in intracellular
+i

102

356

440

Transcription factor EB (TFEB) controls the

Studies

102

In return, the mutations of Glu101 and Gly109,110 in TM9 considerably reduce the catalytic efficiency of the transporter without affecting other subsections (Fig. 4). Genetic change in human NHE1 is related to hypertension, which is clearly related to NHE1 phosphorylation that increases the activation of MAPK pathway. It is suggested that the change in protein kinase pathway possibility results in cation homeostasis, hence leading to hypertension.101

Vacuolar H+ ATPases (V-ATPases)
The V-ATPases are ATP-dependent H+ pumps that show a great variation in the cell membrane. The proteins are composed of several subunits (up to 14), a transmembrane domain is called V0 complex and V1 complex embedded in the cytoplasm. The V-ATPase functions include pH homeostasis, contribution in endocytosis, participation in activation of proteases and invasion of tumor cells. Furthermore, it is involved in several cellular activities such as angiogenesis, autophagy and also interplay with mTOR for amino acids sensing.94,102

Regulation and function of the V-ATPase
The V-ATPases have a wide functional expression in the membranes and intracellular organelles (e.g., endosomes, lysosomes and secretory vesicles) of numerous cells such as neutrophils, macrophages and sperm and tumor cells.101,102 The V0 complex is proton pumpers across the membrane and is formed by a, e, c and c’ subunits. The V1 complex subunits are A, B, C, D, E, F and H, that organized into three subdomains, including:

(i) the A3B3 cylinder (subunits A and B), which is involved in the hydrolysis of ATP,

(ii) the central stalk (subunits D, F and d) that returns energy from ATP to the complex, because the V-ATPase pumps use a rotary mechanism for the transfer of H+ in the cell membrane, and

(iii) the peripheral stalk (subunits E, G, C and H) binds to the A3B3 subdomain and prevents rotation of the stator during ATP hydrolysis.101

Assembly regulation of V-ATPase domains is related to various stimuli. In yeast, glucose depletion causes rapid and reversible decay of V-ATPase, which may help to protect the cell from ATP reserves. It is suggested assembly of V-ATPase is controlled by pH, thus an increase in pH results in the promoted assembly of V-ATPase. In mammalian cells, the V-ATPase pump assembly is stimulated by the activation of phosphoinositide 3-kinase (PI3K) enzyme and mechanistic target of rapamycin complex 1 (mTORC1) in dendritic cells.102

The trafficking regulation is the second main control system of V-ATPase pump activity. This is very important in regulation of proton secretion in epithelial cells in kidney and epididymis. In this regard, high levels of cAMP and an increase in the activity PKA have a positive effect, while AMP kinase has a negative impact. Such effects occur despite the fact that both positive and negative mechanisms use A-subunit for phosphorylation.102 Other regulatory systems in mammalian cells can be referred to as heme-binding protein HRG-1 that, without involvement in the assembly of this pump, increases its activity.102 Transcription factor EB (TFEB) controls the expression of V-ATPase genes, that is under the control of mTORC1.100

The V-ATPase has an important role in intracellular signaling, especially in wingless/int (Wnt) and Notch pathways. In Wnt signaling, if V-ATPase is prohibited either pharmacologically or genetically, Wnt receptor on the cell surface (i.e., LRP6 receptor) cannot be activated. Further, in Notch signal, performance of the V-ATPase is suitable for the activation of Notch receptor. In Notch pathway, when the ligand binds to a cell surface receptor, the receptor breaks structurally, then Notch intracellular domain (NICD) is released and enters into the nucleus. However, if V-ATPase is inactivated, Notch cleavage through γ-secretase occurs in endosomes, and the liberation of NICD can be extremely reduced.102

V-ATPase and cancer
In TME, aerobic and anaerobic metabolisms of glucose lead to the accumulation of acid products that can strongly affect the cancer cells and other neighboring cells. As a result, the pH dysregulation in both pH and pH within TME can influence cancer cells responses such as their response to cytotoxic drugs. It seems that V-ATPase pumps contribute to the reduction of pH and a number of studies suggest that V-ATPase pump activity strongly plays a key role in tumor invasion and cancer cells response to drugs in breast cancer, esophageal carcinoma, lung carcinoma, hepatocellular and pancreatic carcinoma, oral squamous cell carcinoma, sarcoma and other solid tumors.86 Studies have shown that the inhibition of V-ATPase could increase the pH in breast cancer cells, and led to the expression of BNIP3 pre-apoptotic protein and cell death.107 Even short-term inhibition of V-ATPase leads to the activation of cellular stress response and autophagy.109

In mammalian cells, the V-ATPase has four isoforms displayed as a1–a4. The a1 and a2 isoforms, which are present in the membrane of intracellular organelles, have been diagnosed in synaptic vesicles and endosomes, respectively. The a3 and a4 are located in particular cells membrane such as osteoclast cells and renal intercalated cells, respectively.109,110

Recently, it has been shown that V-ATPase contributes to aggressive phenotype of breast cancer cells. The V-ATPase inhibition by specific inhibitors (i.e., baflomycin and concanamycin A) was shown to reduce invasive
It was shown that the increased activity of V-ATPase in metastatic cells could lead to an enhanced autophagy, in which process lysosomes play a fundamental role(s). In addition, it has been shown that the inhibition of mTOR signaling pathway reduces autophagy. Accordingly, it can be an alternative mechanism to proton pump inhibitors because V-ATPase is part of a regulation system that modulates mTOR.98

The expression of E2F1 transcription factor is increased in lung, breast and hepatocellular carcinomas, which is strongly associated with the development of the invasive breast and bladder cancer cells. Accordingly, there have been plenty of evidences that show E2F1 is associated with biological processes such as regulation of cell growth, modulation of autophagy, invasion and metastasis of tumor cells, even though the exact molecular mechanisms are yet to be fully understood. Nathalie et al discovered that E2F1 could contribute to the lysosomal trafficking and mTORC1 signaling, leading to V-ATPase regulation. Their studies showed that E2F1 was able to stimulate the movement of lysosomes in the surrounding cells, and this procedure is necessary for the motivation of mTORC1 which could inhibit autophagy. E2F1 was shown to control the V-ATPase activity through promoting the assembly of V0 and V1 domain in V-ATPase complex. It was shown that the B-subunit of V-ATPase protein could be a suitable target for E2F1 transcription factor, therefore ectopic expression of B-subunit might enhance the activities of V-ATPase and mTORC1.119

Archazolid treatment or silencing of V-ATPase in human breast cancer SKBR3 cells was shown to inhibit the Rac1 activity, and reduce the metastasis of breast cancer by inhibiting the activity of EGFR and Rho-GTPase Rac1 that is important for cell motility.120 Further, a correlative expression between homo sapiens longevity assurance (LASS2), Kruppel-like factor 4 (KLF4) and 1-acylglycerol-3-phosphate O-acyltransferase 9 (AGPAT9) were shown, in which the LASS2 could bind to V-ATPase C-subunit and hence play a role in chemoresistance. The AGPAT9 is a transcription factor and contributes in the inhibition of tumor formation and oncogenesis. The AGPAT9 is a critical enzyme, which is involved in the conversion of glycerol-3-phosphate to lysophosphatic acid in the triacylglycerol synthesis pathway, was shown to specifically inhibit the migration, invasion and metastasis of breast cancer cells. Meanwhile, it has been recently shown that the AGPAT9 functional expression may lead to an increased expression of specific KLF4 gene, perhaps via its direct binding to the promoter region of the LASS2 gene that could induce its expression. Eventually, LASS2 can inhibit the functionality of V-ATPase by binding to its c-subunit.121

V-ATPase inhibitors

The acidic extracellular environment is one of the main features of solid tumors and the V-ATPase has an important role in this process. This milieu provides the necessary condition for tissue damage, elicits the activation of enzymes involved in degradation of ECM, creates a metastatic cell phenotype and is involved in many other unknown biologic processes. Therefore, the

phenotype of breast cancer MDA-MB231 cells.111 It was also shown to contribute to the invasion of other types of tumor cells. For instance, in human pancreatic, increased expression of V-ATPase is associated with an increase in cancer degree.112 Some studies have shown a relationship between rearrangement and arrangement of this pump in plasma membrane and cancer cell invasion.

One limitation on studying this pump is that V-ATPase inhibitors operate specifically and strongly, an hence they prohibit all the intracellular and plasma membrane V-ATPases. This is an important phenomenon because the potential role of intracellular V-ATPase is not considered in the discharge of the invasive factors being mainly growth factors and proteases.113,114 Although the exact mechanism of V-ATPase activity is not clear in the invasion of cancer cells, it is proposed to contribute to the acidification of pH, that is an important factor in the activation of proteins such as cathepsins and matrix metalloproteases.115,116

In colon cancer cells, TM9SF4 protein, as a member of the transmembrane-9 superfamily, was shown to interact with V-ATPase. The function of this protein has been reported in adhesion, phagocytosis and innate immunity. Further, it plays an important role in resistance to the 5-fluorouracil (5-FU) drug and invasive phenotype of cancer cells. The TM9SF4 interacts with the V-ATPase most likely through V1H subunit. It was also reported that the TM9SF4 inhibition could lead to a change in the activity of cancer cells in association with V-ATPase activity reduction in protons outflow. As a result of pH reduction, the extracellular pH and the pH in intracellular vesicles may be increased.117

It has been proven that V-ATPase increase in the membrane of tumor cells is associated with metastasis. The V-ATPase inhibition by archazolid is related to anoikis pathways in the invasive cancer cells. Probably, archazolid inhibits V-ATPase activity with binding to the c-subunit in the V0 domain. Anoikis is a form of programmed cell death which was shown to occur in the cells isolated from the ECM, while metastatic cancer cells are resistant to such phenomenon. The anoikis begins with two pathways, including: (i) extrinsic pathway, where cell death receptors are involved and caspase-8 and Bcl-2 are the main players, and (ii) the intrinsic pathway that starts from mitochondria and is related to cytochrome C.

As mentioned, V-ATPase plays an important role in autophagy, in which the cells detached from ECM stimulate autophagy as a process to evade anoikis. Hence, the V-ATPase inhibition can be effective in stimulating anoikis. Recently, a number of studies have suggested that endolysosomal V-ATPase are attractive targets for inducing anti-tumor and anti-metastasis effects, since its inhibition could prevent the endocytotic traffic of migratory signaling molecules such as Rac1 and EGF receptor.118

It should be stated that the increased activity of V-ATPase in metastatic cells could lead to an enhanced autophagy, which process lysosomes play a fundamental role(s). In
employment of V-ATPase inhibitors can suppress all these events and increase the survival rate of cancer patients. The first V-ATPase inhibitor was bafilomycin that has a microbial origin isolated from *Streptomyces griseus*. Another inhibitor is concanamycin that has been isolated from the *Streptomyces meyagawaensis*.

Archazolid inhibitor is similar to bafilomycin or concanamycin because it is able to attach to the c-subunit of V-ATPases. Furthermore, it has been shown that this compound has an important anti-tumor role both in vitro and in vivo. Archazolid is produced by *Cystobacter violaceus* and *Archangium gephyra*. Benzolactone enamides are another group of V-ATPases inhibitors, which are normally isolated from sea sponges, gram-negative bacteria, and ascidians. Key members of the family of V-ATPase inhibitors include salicylhalamid A, apicularen A, lobatamide A, oximidine I, and cruentaren. In addition to the listed cases, new V-ATPases inhibitors continue to be discovered and added to the list, including: NiK12192, PPI SB 242784 and FR202126.

The breast tumor cells treated with bafilomycin A1 were shown to significantly lose their metastatic and tumor projection. These results might be related to the findings that cancer cells with low metastatic potential use HCO$_3^-$ and NHE1 transporter to regulate the pH, while the high-metastatic cancer cells use of V-ATPase proton pump for this purpose. It was shown that V-ATPase inhibition by bafilomycin or concanamycin could induce apoptosis. In this context, human gastric cancer cells were evaluated and lysosomal pH factor was studied, with results showing some changes could occur in lysosomal pH. Further, it was found that an increase in the existence of bafilomycin might lead to an increase in the activity of caspase-3.

To date, several related factors between lysosomes and cancer have been identified.

In short, the lysosomes have an acidic milieu which is controlled by V-ATPase, hence it can be considered as a potential therapeutic target for cancer therapy. The pH in the normal cell lysosomes is about 5. However, in cancer cells, the pH in lysosome may be changed (e.g., 5.8 in MCF-7 cancer cells and 6.4 in promyelocytic leukemia HL-60 cancer cells). The reasons for such alterations could be due to (i) malignancy-related changes or (ii) treatment with drugs (e.g., V-ATPase inhibition with bafilomycin A).

Ellipticin displays anti-tumor effects, and it is topoisomerase II inhibitor by DNA intercalation. Recently, it has been observed that treatment of the UKF-NB-4 cells with this inhibitor might increase the expression of V-ATPase. Therefore, the V-ATPase activity could result in lysosome alkalization and resistance of UKF-NB-4ELLI1 cells to ellipticine-induced apoptosis. In this regard, the V-ATPase inhibition by concanamycin A might reduce the acidity of lysosomes in the PKSV-PR cells.

**Carbonic anhydrases**

The aberrant metabolism of cancer cells may lead to the production of proton and carbon dioxide (CO$_2$), which can be converted into carbonic acids by the carbonic anhydrases (CAs) - a process that occurs due to high consumption of glucose. Many proteins are involved in the metabolism of glucose such as glucose transporters and pH regulatory proteins. Of these, carbonic anhydrase family plays an important role, especially CAIX and CAXII. It should be noted that little change (even 0.1 pH units) in the intracellular and extracellular pH could disrupt the molecular functions of solid tumor cells, including: ATP synthesis, enzyme functionalities, migration, invasiveness and metastasis. Also, different isoforms of extracellular proteins (e.g., fibronectin and tenascin) might be generated by alternative splicing that may not occur in the normal cells.

The carbonic anhydrases are zinc metalloproteinase enzymes which can be found among all organisms, including in microbes, fungi, plants, and animals. Five groups of carbonic anhydrases (α, β, γ, δ, and ζ) have evolved independently, among which alpha-carbonic anhydrases were found in the human. There are 16 isoforms of alpha-carbonic anhydrase in primates, 15 isoforms of which are common and also shared in human. They are classified based on their location in the cell, catalytic activity and response to several groups of inhibitors, as follows: (i) some are placed in the cell membrane (CAI, CAII, CAIII, CAVII and CAXIII), (ii) several are attached to the membrane (CAIV, CAIX, CAXII and CAXIV), (iii) two of them are found in the mitochondria (CAVA and CAVB) and (iv) secretory isoforms (CAVI), three of them are catalytic isoforms, so-called CA-related proteins (CARPs) which include CAVIII, CAX and CAXI.

The carbonic anhydrases perform a vital reaction in cells, that is: “CO$_2$ + H$_2$O$\leftrightarrow$HCO$_3^-$ + H$^+$”. Also, CA isoforms are involved in many process and functions in mammals. Among the most important ones, we can point out the acid-base balance, release of electrolytes, bone resorption, calcification, lipogenesis, gluconeogenesis and ureagenesis in human. Further, this enzyme appears to contribute in photosynthesis and carbon dioxide fixation reaction in bacteria and plants. In human, CAs are present in a very wide range of tissues. In fact, they are present almost in most tissues, including: digestive, nervous and genital systems, renal, lungs, skin and others organs. In 1992, Pastoreková et al showed that CAs are associated with cancer. Thus, it became clear that CAIX and CAXII increase simultaneously in many tumor tissues and normal tissue could be related to the cancer development and progression.

Sulphonamides, sulphamates and sulphamides are the main compounds for inhibition of carbonic anhydrases, which are able to bind to zinc ion and active site of the enzyme resulting in their inactivation. It has been over 50 years that sulphonamides have been used as diuretics and antiglaucoma medicine. Now, this component is proposed as anticonvulsant, anti-obesity, anticancer and anti-pain agent. Various compounds have been designed for the inhibition of carbonic anhydrases, and some of them are mentioned in the following context.
Fluorescent sulphonamides are used for imaging purposes and CAs are involved in tumor acidity. Addition of positive and negative charges to sulphonamide and sulphamate enable them more likely to cross the cell membrane and influence the intracellular CAs such as CAIX and CAXII.

Acetazolamide inhibits all CA isoforms with a high capability. To date, new acetazolamide derivatives have been produced with much better and efficient functional properties than the parent drug acetazolamide.

Sugar-containing sulfonamides-sulfamates-sulfamides are extremely hydrophilic compounds that cannot easily cross the cell membrane. Thus, they influence the extracellular CAs, including CAIX and CAXII.

Coumarins, thiocoumarins and polyamines are new chemotypes that have CAs inhibitory properties. These inhibitors bind to CAs active site and do not have interaction with zinc ions of this enzyme.

Protein tyrosine kinase (PTK) inhibitors (e.g., imatinib and nilotinib) are also the CAs inhibitors.

Fig. 5. Subcellular localization, transmembrane topology and sequence processing of carbonic anhydrase IX (CAIX). A) The residues from 436 to 459 that is localized in cytoplasm. B) The residues from 38 to 414 that known as extracellular domain. C) Transmembrane segment of the CA9 between amino acids 415 – 435. D) The N-terminal signal peptide at the first 37 residues are denoted as signal peptide.

Fig. 6. Functional sites, disulfide bond and post-translational modifications of the carbonic anhydrase IX. A) Zinc binding to the histidine 226, 228 and 251 require a catalytically activity for the CA9 protein. B) Histidine 200 act as a proton acceptor that is crucial for the enzyme catalysis activity. C) The positions of cysteine 156 and 336 that are participated in formation of disulfide bond. D and E) the O- and N-linked glycosylation relating to threonine 115 and asparagine 346.
however, they are not as effective as sulphonamides and coumarins.\(^{139,140}\)

(vii) Monoclonal antibodies such as M75 and WX-G250 have also been used.\(^{141,142}\)

(viii) CA inhibitors coated gold nanoparticles have also been used.\(^{143}\)

**Structure and function of CAIX in tumor cells**

CAIX seems to be more complex than the other isoforms of CAs. Unlike other isoforms that contain a polypeptide chain with just one domain, CAIX is a multidomain protein (Fig. 5). The CAIX isoform is comprised of (i) a short intracytotoxic sector with an unknown role, (ii) a small transmembrane section, (iii) an extracellular catalytic domain, (iv) a proteoglycan like domain that exclusively belongs to CAIX - not seen in other isoforms - and is involved in cell adhesion processes, and (v) a stocky peptide signal.

CAIX may be seen in the form of a dimer, in which they may be connected to each other through disulfide bonds. Among CAs protein families, CAIX has a high catalytic activity. The catalytic domain of this protein contains zinc (Zn\(^{2+}\)) ion as well as three histidine amino acids and a water molecule (Fig. 6).\(^{131}\)

CAIX is highly expressed in a variety of different types of cancers, whose expression is regulated by the transcription factor HIF-1 and is highly induced in the hypoxic condition, and also associate with the cellular responses to radiotherapy and chemotherapy.\(^{132}\) The transcription factor HIF-1 consists of two subunits, i.e., alpha (α) and beta (β). In normoxia, the unit α is connected to pVHL (von Hippel–Lindau tumor suppressor protein), and therefore prevents the assembly of two subunits of α and β. However, under hypoxia, pVHL is separated from the unit α and leads to the connection of two α and β subunits to each other, at which point an active form of HIF-1 is created. Such phenomena result in the functional expression of the hypoxia responsive elements (HREs) such as glucose transporters (GLUT-1 and GLUT-3), vascular endothelial growth factor (VEGF) and CAIX.\(^{136,138,144}\) Of these, CAIX contributes to the acidification of TME. It may also lead to the phenotype of metastasis. Moreover, this isoform is involved in the pH regulation and cellular connection in association with ion exchanger and Na\(^{+}\)-HCO\(_3^{-}\) co-transporters.\(^{145-147}\) Studies have shown that CAIX expression is under the control of promoter methylation in the kidney cells, which is an epigenetic mechanism.\(^{146}\)

Reports have shown that inactivation of CAIX gene with short hairpin RNA or inhibition of catalytic domain activity by drug could lead to a decrease in xenograft tumor size. Further, CAXII mRNA levels are upregulated in some cancer cells such as LS174Tr and HT29. Overall, suppression of both CAIX and CAXII appears to be the reason for 85% reduction in tumor growth. Intriguingly, CAIX expression in cancer cells could be a compensatory response to reduce the damaging effects of acidosis and hypoxia.\(^{148-150}\) The use of CAIX inhibitors reduces proliferation of cancer cells and increases apoptosis in hypoxic conditions, sensitizing cancer cells to chemotherapy and radiotherapy.\(^{151}\) The membrane transporters, pH regulation machineries (e.g., CAIX) and hypoxia in cancer cells are mostly located in invadopodia areas (i.e., membranous actin-rich protrusions of the cells). Using the import mechanism of HCO\(_3^{-}\} and export mechanism of H\(^+\}, lactate and CO\(_2\) are able to facilitate the cell movement.\(^{152}\) Special conditions of solid tumors (i.e., low pH, hypoxia and its molecular responses) allow cancer cells to show stem cell-like phenotype.\(^{153,154}\) In esophageal cancer model, it was found that the expression of CAIX and some other genes (i.e., Sox-2, Nanog and Lin28) are related to an increase in stem cell-like phenotype.\(^{155}\) Studies about breast cancer have shown that the expression of CAIX with stem cell-related factors is increased markedly.\(^{156,157}\) The expression of CAIX is related to the expression of CD44, which is a stem cell marker. Besides, CAIX contributes to the activation of EMT phenomenon in epithelial cancer cells.\(^{153,155}\) It has been shown that the overexpression CAIX is involved in the formation of focal adhesion in the cells.\(^{159}\) It associate with β-catenin and the separation of E-cadherin from cytoskeletal - a key process for the separation of cell-cell junction.\(^{160}\) Further, the activations of PI3K/Akt and FAK/PI3K/mTOR/p70S6K pathways seem to be in association with CAIX.\(^{161,162}\)

**Present and future prospects**

Solid tumors display complex hallmarks. They are able to form a permissive microenvironment and show adaptation and evolution ed through functional expression of a number of different molecular machineries. Such traits make the treatment of solid tumors very hard. Although acid-base balance in cells is one of the main parameters to cellular homeostasis, unfortunately, this balance is disturbed in solid tumors. This is a unique characteristic of solid tumors, which seems to be initiated by hypoxia and aberrant metabolism of glucose resulting in production of acidic byproducts in cancerous cells. Such phenomena give rise to functional expression of array of functional proteins including transcription factors, enzymes and transporters. These biological elements are considered as potential targets, inhibition of which may provide effective pharmacotherapy in combination with chemotherapy and/or immunotherapy. Use of the proton transporter inhibitors as a new treatment for cancer were proposed by several research groups. Pouyssegur group showed that use of these this inhibitor in combination with anti-angiogenic inhibitors could effectively abolish the solid tumors.\(^{17}\) One advantage of this treatment modality seems to be the induction of less toxicity in comparison with the traditional chemotherapy strategies. In fact, the main purpose of this method was based on acid-base balance, employing the forces involved in controlling pH dysregulation in cancer cells and tissue, resulting in regression of tumor growth, prohibition of invasion and suppression of metastasis. This has been shown in many different human solid tumors.
This could be beneficial because such treatment may lead to the inhibition of metastasis process and neutralization of drug resistance, resulting in much more sensitization of cancer cells to chemotherapy, radiotherapy and immunotherapy. Cancer cells in different tissues show distinctive behaviors because they have different genetic pattern and mutations or expression. For instance, lower metastatic cells in breast cancer often use NHEs and HCO$_3$- based transporting system to transfer proton, whereas extremely metastatic cells employ plasma membrane V-ATPases.\textsuperscript{163} This issue is also true about CAs, for example, CAII mRNA level was shown to be decreased in the lung and colon cancers, while the level of CAIX mRNA was reported to be extremely increased in basal and triple-negative breast cancers. Further, CAXII mRNA levels was shown to be substantially enhanced in all types of breast cancer. In accordance with these, CAIX and CAXII mRNA levels were reported to be increased in squamous cell carcinoma of the lung, but not in the lung adenocarcinomas.\textsuperscript{164} A variety of mechanisms are involved in pH-dependent cancer cells’ behaviors such as proliferation and survival, metabolic adaptation, metastatic and invasion. Detection of the molecular basis of this phenomenon is very important in understanding of how pH dysregulation can influence the progression and metastasis of solid tumors. It is now well-known that an increased pH$_i$ is in favor of cancer cells proliferation, and it also increases the cell survival through inhibition of apoptosis. In such circumstances, cancer cells proliferation seems to be somewhat independent from the influence of growth factors. Further, cancer cells need high energy and nucleotid biosynthesis for growth and proliferation in comparison with normal cells. As a result, metabolic program changes in cancer cells, which is known as the Warburg effect or ‘aerobic’ glycolysis. In solid tumors, cancerous cells are able to modulate/remodel the ECM through pH dysregulation resulting in metastasis. The pH$_i$ increase seems to necessary for the migration of cells, while the pH$_i$ decrease appears to interfere with the degradation of ECM that favors further invasion of cancer. Researchers who attempt to discover pH dysregulation in solid tumors have focused on proton transport, while other ions may be involved in the cancer, including HCO$_3$. However, many fundamental questions remain unanswered. We need to address how cancer cells get capability to escape from the immune system surveillance within TME? What are the holistic roles of solute transporters? How the vesicular enzymes behave in lower pH$_i$? Is pH$_i$ dysregulation involved in anoikis? How single cancer cells communicate with neighboring cells during metastasis? How different types of cells communicate with TME? And, many other questions.

We have previously capitalized on development of immunotherapies and various multifunctional nanomedicines to combat different types of solid tumors.\textsuperscript{165-162} However, it seems that ultimate therapy of solid tumors might need use of robust synthetic lethality through combination therapy via targeting different key molecules involved in the dysregulation of pH, formation of TME, tumor vascularization, and even tumor metabolism. He main aim of this review was to bring about the importance of molecular machineries related to the pH dysregulation within TME and that the use of relevant inhibitors against key regulators of pH might suppress tumor progression, metastasis and further invasion. It can be suggested that targeting the key elements involved in formation of TME and pH$_i$ along with other conventional therapies can sensitize cancer cells to combinational therapy and hence reduce drug resistances. This may improve the survival rate of cancer patients. It should be also noted that the cancerous cells in different part of solid tumors may present distinct molecular patterns in terms of pH$_i$ dysregulation, and hence some proof-of-concept conforming studies on epigenetic/genetic and proteomic/metabolomic aspects may help us to design much more effective treatment modalities to improve the currently used chemotherapeutic and immunotherapeutic.

### Review Highlights

#### What is current knowledge?
- Cancer is characterized by several adaptive hallmarks.
- Cancer cells are able to form permissive tumor microenvironment (TME).
- Hypoxia, glycolysis and Warburg effects are the main causes for the formation of TME.
- The pH$_i$ dysregulation is resultant from aberrant metabolism of glucose and production of acidic byproducts. Cancer cells migration.

#### What is new here?
- Dysregulated pH$_i$ appears to be part of cancer hallmarks.
- The pH$_i$ dysregulation favors migration, metastasis and invasion of cancer cells.
- Combined formulation of cytotoxic agents with different inhibitors of pH modulators in TME may provide a robust synthetic lethality against solid tumors.
- The pH$_i$ dysregulation machineries in TME may be considered as tumor molecular markers and used for cancer diagnosis.
- Targeted therapy of cancer can be done by targeting pH$_i$ modulators.

### Acknowledgment

The authors are very grateful for the financial support (grant No: RCPN-94012) provided by the Research Center for Pharmaceutical Nanotechnology (RCPN), BioMedicine Institute, Tabriz University of Medical Sciences.

### Conflict of interest

Authors declare no conflict of interest in this study.

### Ethical approval

Not applicable.

### References

1. Barar J, Omidi Y. Dysregulated pH in Tumor Microenvironment
pH dysregulation in tumor microenvironment

Checkmates Cancer Therapy. Bioimpacts 2013; 3: 149-62. doi:10.5681/bi.2013.036

Webb BA, Chimenti M, Jacobson MP, Barber DL. Dysregulated pH: a perfect storm for cancer progression. Nat Rev Cancer 2011; 11: 671-7. doi:10.1038/nrc3110

Busco G, Cardone RA, Greco MR, Bellizzi A, Coletta M, Antelmi E, et al. NHE1 promotes invasiodploid ECM proteolysis through acidification of the peri-invadopodial space. Faseb J 2012; 24: 3903-15. doi:10.1096/fj.09-149518

Amith SR, Fliegel L. Regulation of the Nα/H+ Exchanger (NHE1) in Breast Cancer Metastasis. Cancer Res 2013; 73: 1259-64. doi:10.1158/0008-5472.can-12-4031

Lin Y, Chang G, Wang J, Jin W, Wang L, Li H, et al. NHE1 mediates MDA-MB-231 cell invasion through the regulation of MT1-MMP. Exp Cell Res 2011; 317: 2031-40. doi:10.1016/j.yexcr.2011.05.026

Daniel C, Bell C, Burton C, Hargrundшей S, Reshkin SJ, Rauch C. The role of proton dynamics in the development and maintenance of multidrug resistance in cancer. Biochim Biophys Acta 2013; 1832: 606-17. doi:10.1016/j.bbadis.2013.01.020

Macheda ML, Rogers S, Best JD. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol. 2005; 202(3): 654-62. doi:10.1002/jcp.20166

Heinrich EL, Walser TC, Krysan K, Lidician EL, Grant JL, Rodriguez NL, et al. The inflammatory tumor microenvironment, epithelial mesenchymal transition and lung carcinogenesis. Cancer Microenviroon 2012; 5: 5-18. doi:10.1002/mmci.2012307-011-0089-0

Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer’s Achilles’ heel. Cancer Cell 2008; 13: 472-82. doi:10.1016/j.ccr.2008.05.005

Vander Heiden MG, Cantley LC, Thompson CB. Understanding cancer: the metabolic basis of cell proliferation. Science 2009; 324: 1029-33. doi:10.1126/science.1160809

Paget S. The distribution of second growths in the breast. 1889. Cancer Metastasis Rev 2009; 8: 98-101.

Fidler II. The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer 2003; 3: 453-8. doi:10.1038/nrc1098

Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment. Science 2015; 348: 74-80. doi:10.1126/science.aaa6204

Balkwill FR, Capasso M, Hagemann T. The tumor microenvironment at a glance. J Cell Sci 2012; 125: 5591-6. doi:10.1242/jcs.116392

Romero-Garcia S, Moreno-Altamirano MM, Prado-Garcia H, Sanchez-Garcia FJ. Lactate contribution to the tumor microenvironment: Mechanisms, effects on immune cells and therapeutic relevance. Frontiers in Immunology 2016; 7. doi:10.3389/fimmu.2016.00052

Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to angiogenesis and immune escape. Carcinogenesis 2009; 30: 1073-81. doi:10.1093/carcin/bgp127

Cramer DW, Finn OJ. Epidemiologic perspective on immune-surveillance in cancer. Curr Opin Immunol 2011; 23: 265-71. doi:10.1016/j.coi.2011.01.002

Tsai MJ, Chang WA, Huang MS, Kuo PL. Tumor microenvironment: a new treatment target for cancer. ISRN Biochem 2014: 351939. doi:10.1155/2014/351939

Mao X, Kang HZ, Garfield DH, Shen K, Wang J. Stromal cells in tumor microenvironment and breast cancer. Cancer Metastasis Rev 2013; 32: 303-15. doi:10.1007/s10555-012-9415-3

Shain KH, Dalton WS. Environmental-mediated drug resistance: a new treatment target for cancer. ISRN Biochem 2011; 324: 1729-35. doi:10.5177/9781848217938

Fontanil T, Rua S, LLamazares M, Moncada-Pazos A, Quirós PM, Garcia-Suarez O, et al. Interaction between the ADAMTS-12 metalloproteinase and fibrilin-2 induces tumor-suppressive effects in breast cancer cells. Oncotarget 2014; 5: 1253-64. doi:10.18632/oncotarget.1690

Mayoar-Guilliani A, Erler JT. The potential for targeting extracellular LUX proteins in human malignancy. Onco Targets Ther 2013; 6: 1729-35. doi:10.2147/ott.s38110

Penttinen R. Extracellular matrix molecules: potential targets in pharmacotherapy. Pharmacol Rev 2009; 61: 198-223. doi:10.1124/pr.109.001287

Fontanil T, Rua S, LLamazares M, Moncada-Pazos A, Quirós PM, Garcia-Suarez O, et al. Interaction between the ADAMTS-12 metalloproteinase and fibrilin-2 induces tumor-suppressive effects in breast cancer cells. Oncotarget 2014; 5: 1253-64. doi:10.18632/oncotarget.1690

Mayoar-Guilliani A, Erler JT. The potential for targeting extracellular LUX proteins in human malignancy. Onco Targets Ther 2013; 6: 1729-35. doi:10.2147/ott.s38110

Fontanil T, Rua S, LLamazares M, Moncada-Pazos A, Quirós PM, Garcia-Suarez O, et al. Interaction between the ADAMTS-12 metalloproteinase and fibrilin-2 induces tumor-suppressive effects in breast cancer cells. Oncotarget 2014; 5: 1253-64. doi:10.18632/oncotarget.1690
Mesenchymal stem cells induce resistance to Endothelin A receptor/beta-arrestin signaling to the Wnt/Beta-catenin pathway. Brevican, neurocan, tenascin-C and versican are mainly synthesized by tumor-associated fibroblasts and may act as chaperones for metastasis. Macrophages and cathepsin proteases blunt chemotherapeutic efficacy of weak acid and base chemotherapeutics. Gerweck LE, Vijayappa S, Kozin S. Tumor pH controls the in vivo efficacy of methotrexate through solid tissue. Cowan DS, Tannock IF. Factors that influence the penetration of topoisomerase-targeted drugs. Tomida A, Tsuruo T. Drug resistance mediated by cellular stress and the unfolded protein response is necessary and sufficient for reducing cell contact and kinetics. Cowen DS, Tannock IF. Acid pH in tumors and its potential for therapeutic exploitation. Guo YS, Jin GF, Houston CW, Thompson JC, Townsend CM. Anticancer Drug Des 1999; 14: 169-77. Wang GL, Semenza GL. Purification and characterization of hyposia-inducible factor 1. J Biol Chem 1995; 270: 1230-7. Tannock IF, Rotin D. Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res 2005; 65: 2077-84. Asgharzadeh et al. BioImpacts, 2017, 7(2), 115-133
isoform NHE-1 in rabbit kidney. Am J Physiol 1992; 263: F833-40.
82. Petrecca K, Atanasiu R, Grinstein S, Orłowski J, Shrier A. Subcellular localization of the Na+/H+ exchanger NHE1 in rat myocardium. Am J Physiol 1999; 276: H709-17.
83. Malo ME, Fliegel L. Physiological role and regulation of the Na+/H+ exchanger. Can J Physiol Pharmacol 2006; 84: 1081-95. doi:10.1139/y06-065
84. Putney JK, Denker SP, Barber DL. The changing face of the Na+/H+ exchanger, NHE1: structure, regulation, and cellular actions. Amn Rev Pharmacol Toxicol 2002; 42: 527-52. doi:10.1146/annurev.toxic.42.092001.143801
85. Tomina T, Ishizaki T, Narumiya S, Barber DL. p16(0)ROCK mediates RhoA activation of Na+-H+ exchange. Emb j 1998; 17: 4712-22. doi:10.1093/embj/17.16.4712
86. Khaled AR, Moor AN, Li A, Kin K, Ferris DK, Muegge K, et al. Trophic factor withdrawal: p38 mitogen-activated protein kinase activates NHE1, which induces intracellular alkalinization. Mol Cell Biol 2001; 21: 7945-57. doi:10.1128/mcb.21.22.7345-7357.2001
87. Matsushita M, Tanaka H, Mitsui K, Kanazawa H. Dual functional significance of calcineurin homologous protein 1 binding to Na+/H+ exchanger isoform 1. Am J Physiol Cell Physiol 2011; 301-C280-8. doi:10.1152/ajpcell.00420.2010
88. Pang T, Wakabayashi S, Shigekawa M. Expression of calcineurin B homologous protein 2 protects serum deprivation-induced cell death by serum-independent activation of Na+/H+ exchanger. J Biol Chem 2002; 277: 45771-7. doi:10.1074/jbc.M203183200
89. Li QH, Wang LH, Lin YN, Chang GQ, Li HW, Jin WN, et al. Nuclear accumulation of calcineurin B homologous protein 2 (CHP2) results in enhanced proliferation of tumor cells. Genes Cells 2011; 16: 416-26. doi:10.1111/j.1365-2443.2011.01497.x
90. Li X, Liu Y, Kay CM, Muller-Esterl W, Fliegel L. The Na+/H+ exchanger cytoplasmic tail: structure, function, and interactions with tescalcin. Biochemistry 2003; 42: 7448-56. doi:10.1021/bi0207143d
91. Aharonovitz O, Zaun HC, Balla T, York JD, Orlowski J, Grinstein S, et al. Subcellular localization of the Na+/H+ exchanger NHE1 in rat myocardium. Am J Physiol 2001; 276: H709-17.
92. Sliva NL, Haworth RS, Singh D, Fliegel L. The carboxyl-terminal anhydrase II binding site regulates NHE1 activity.
93. Li X, Liu Y, Alvarez BV, Casey JR, Fliegel L. A novel carbonic anhydrase II-dependent TAT, Zou L, et al. Regulation of TFEB and V-ATPases by mTORC1. EMBO J 2011; 30: 3242-58. doi:10.1038/embj.2011.257
94. Graham RM, Thompson JW, Webster KA. Inhibition of the vascular ATPase induces Bnip3-dependent death of cancer cells and a reduction in tumor burden and metastasis. Oncotarget 2014; 5: 1162. doi:10.18632/oncotarget.14699
95. von Schwarzenberg K, Wiedmann RM, Oak P, Schulz S, Zischka H, Wanner G, et al. Mode of cell death induction by pharmacological vascular H+-ATPase inhibition. J Biol Chem 2013; 288: 1385-96. doi:10.1074/jbc.M112.412007
96. Toyomura T, Oka T, Yamaguchi C, Wada Y, Futai M. Three subunit isoforms of mouse vascular H+-ATPase. Preferential expression of the a3 isoform during osteoclast differentiation. J Biol Chem 2000; 275: 8760-5. doi:10.1074/jbc.275.12.8760. doi:10.1074/jbc.275.12.8760
97. Smith AN, Skag J, Choate KA, Nayir A, Bakkaloglu A, Ozen S, et al. Mutations in ATP6V1B1, encoding a new kidney vacuolar H+-ATPase proton pump 116-kD subunit, cause recessive distal renal tubular acidosis with preserved hearing. Nat Genet 2000; 26: 71-5. doi:10.1038/79208
98. Cotter K, Capacci J, Sennoue S, Huss M, Maier M, Martinez-Zaguarregui R, et al. Activity of Plasma Membrane V-ATPases Is Critical for the Invasion of MDA-MB231 Breast Cancer Cells. J Biol Chem 2015; 290(6):3680-92. doi:10.1074/jbc.M114.611210.
99. Chung C, Mader CC, Schmitz JC, Atladjott J, Fitcher P, Cornwell ML, et al. The vascular-ATPase modulates matrix metalloproteinase isoforms in human pancreatic cancer. Lab Invest 2011; 91(5):732-43. doi:10.1038/labinvest.2011.8.
100. Nishishio T, Hata K, Nakanshi M, Morita Y, Sun-Wada G-H, Wada Y, et al. The a3 isofrom vascular type H+-ATPase promotes distant metastasis in the mouse B16 melanoma cells. Mol Cancer Res 2011; 9: 845-55. doi:10.1158/1541-7786.MCR-10-0449.
101. Hendrix A, Sormunen R, Westbroek W, Lambein K, Denys H, Gondi CS, Rao JS. Cathepsin B as a cancer target. Biochimica et Biophysica Acta (BBA)-Biomembranes 2014; 1842: 90-100. doi:10.1016/j.bbamem.2013.09.002.
Asgharzadeh et al. (2017) investigated the role of hypoxia in tumor progression. They explored the efficacy of carbonic anhydrase inhibitors in targeting hypoxia-associated mechanisms. The study also highlighted the potential of these inhibitors in inducing apoptosis and suppressing tumor growth.

Hypoxia, a hallmark of many tumors, is known to promote angiogenesis, metastasis, and chemotherapy resistance. Asgharzadeh et al. demonstrated that carbonic anhydrase inhibitors hold promise for targeting hypoxia and improving treatment outcomes in cancer.

The authors used a combination of in vitro and in vivo models to assess the efficacy of these inhibitors. They found that carbonic anhydrase inhibitors, by modulating intracellular pH, could enhance the effectiveness of chemotherapeutic agents.

The results suggest that carbonic anhydrase inhibitors could serve as a valuable tool in the therapeutic arsenal against hypoxia-driven cancers. Further clinical trials are needed to validate these findings and establish the safety and efficacy of these inhibitors in clinical settings.
stem cells from esophageal squamous cell carcinoma cells. *Biochem Biophys Res Comm* 2013; 434: 773-8. doi: 10.1016/j.bbr.2013.04.008.

156. Sansone P, Storci G, Giovannini C, Pandolfi S, Pianetti S, Taffurelli M, et al. p66Shc/Notch-3 Interplay Controls Self-Renewal and Hypoxia Survival in Human Stem/Progenitor Cells of the Mammary Gland Expanded In Vitro as Mammospheres. *Stem Cells* 2007; 25: 807-15. doi:10.1634/stemcells.2006-0442.

157. Storci G, Sansone P, Treve D, Tavolari S, Taffurelli M, Cecchelli C, et al. The basal-like breast carcinoma phenotype is regulated by SLUG gene expression. *J Pathol* 2008; 214: 25-37. doi:10.1002/path.2254.

158. Fiaschi T, Giannoni E, Taddei L, Cirri P, Marini A, Pintus G, et al. Carbonic anhydrase IX from cancer-associated fibroblasts drives epithelial-mesenchymal transition in prostate carcinoma cells. *Cell Cycle* 2013; 12: 1791-801. doi: 10.4161/cc.24902.

159. Csaderova L, Debrova M, Radvák P, Stano M, Vrestiakova M, Kopacek J, et al. The effect of carbonic anhydrase IX on focal contacts during cell spreading and migration. *Front Physiol* 2013; 4: 103389. doi: 10.3389/fphys.2013.00271.

160. Švétová E, Žílka N, Zaťovcová M, Gabidulinová A, Čiampor P, Pastorek J, et al. Carbonic anhydrase IX reduces E-cadherin-mediated adhesion of MDCK cells via interaction with β-catenin. *Exp Cell Res* 2003; 290: 332-45. doi.org/10.1016/S0014-4827(03)00351-3.

161. Doral T, Sawczuk IS, Pastorek J, Wiernik PH, Dutsch JP. The role of carbonic anhydrase IX overexpression in kidney cancer. *Exp Cell Res* 2005; 41: 2935-47. doi:10.1016/S0014-4827(03)00351-3.

162. Wiesener MS, Münchenhagen PM, Berger I, Morgan NV, Roigas J, Schwertz A, et al. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1α in clear cell renal carcinomas. *Cancer Res* 2001; 61: 5215-22.

163. Sennoune SR, Bakunts K, Martinez GM, Chu-Tuan JL, Kebir Y, Attaya MN, et al. Vacuolar H+-ATPase in human breast cancer cells with distinct metastatic potential: distribution and functional activity. *Am J Physiol Cell Physiol* 2004; 286: C1443-C52. doi:10.1152/ajpcell.00407.2003.

164. Gorbatenko A, Olesen CW, Roediger E, Pedersen SF. Regulation and roles of bicarbonate transporters in cancer. *Front Physiol* 2013; 5: 130. doi:10.3389/fphys.2013.01030.

165. Shakoori Z, Ghanbari H, Omidi Y, Pashaei Asl R, Akbarzadeh A, Jomeh Farsangi Z, et al. fluorescent multi-responsive cross-linked P(N-isopropylacrylamide)-based nanocomposites for cisplatin delivery. *Drug Dev Ind Pharm* 2017; 43: 1283-91. doi:10.1080/03639045.2017.1315859.

166. Rahmanian N, Eskandani M, Barar J, Omidi Y. Recent trends in targeted therapy of cancer using graphene oxide-modified multifunctional nanomedicines. *J Drug Target* 2017; 25: 202-15. doi:10.1080/1061186X.2016.1238475.

167. Bakhshiary Z, Barar J, Aghanejad A, Saei AA, Nemati E, Esatiz Nazhad Dolatabadi I, et al. Microparticles containing erlotinib-loaded solid lipid nanoparticles for treatment of non-small cell lung cancer. *Drug Dev Ind Pharm* 2017; 43: 1244-53. doi:10.1080/03639045.2017.1310232.

168. Same S, Aghanejad A, Akbari Nakhjavan S, Barar J, Omidi Y. Radiolabeled theranostics: magnetic and gold nanoparticles. *Bioimpacts* 2016; 6: 169-81. doi:10.15171/bi.2016.23.

169. Johari-Ahar M, Barar J, Aliizadeh AM, Davaran S, Omidi Y, Rashidi MR. Methotrexate-conjugated quantum dots: synthesis, characterisation and cytotoxicity in drug resistant cancer cells. *J Drug Target* 2016; 24: 120-33. doi:10.3109/1061186X.2015.1058801.

170. Azhdarzadeh M, Atabie S, Saei AA, Varnamkhasti BS, Omidi Y, Fateh M, et al. Theranostic MUC-1 aptamer targeted gold coated superparamagnetic iron oxide nanoparticles for magnetic resonance imaging and photothermal therapy of colon cancer. *Colloids Surf B Biointerfaces* 2016; 143: 224-32. doi:10.1016/j.colsurfb.2016.02.058.

171. Barar J, Kafli V, Majd MH, Barzegar A, Khan S, Johari-Ahar M, et al. Multifunctional mitochondrion-conjugated magnetic nanosystem for targeted therapy of folate receptor-overexpressing malignant cells. *J Nanobiotechnology* 2015; 13: 26. doi:10.1186/s12951-015-0083-7.

172. Mathiasen EI, Barar J, Sandaltzopoulos R, Li C, Cokouo G, Omidi Y, Shikonin-loaded antibody-armed nanoparticles for targeted therapy of ovarian cancer. *Int J Nanomedicine* 2014; 9: 1855-70. doi:10.2147/IJNN.S31880.

173. Mashinchian O, Johari-Ahar M, Ghaemi B, Rashidi M, Barar J, Omidi Y. Impacts of quantum dots in molecular detection and bioimaging of cancer. *Bioimpacts* 2014; 4: 149-66. doi:10.15171/bi.2014.008.

174. Barar J, Omidi Y. Surface modified multifunctional nanomedicines for simultaneous imaging and therapy of cancer. *Bioimpacts* 2014; 4: 3-14. doi:10.5681/bi.2014.011.

175. Tohidkia MR, Asadi F, Barar J, Omidi Y. Selection of potential therapeutic human single-chain Fv antibodies against cholecystokinin-B/gastrin receptor by phage display technology. *BioDrugs* 2013; 27: 55-67. doi:10.1007/s40264-012-0007-0.

176. Najar AG, Pashaei-Asl R, Omidi Y, Farajnia S, Nourazarian AR. EGFR antisense oligonucleotides encapsulated with nanoparticles decrease EGFR, MAPK1 and STAT5 expression in a human colon cancer cell line. *Asian J Cancer Prev* 2013; 14: 495-8.

177. Heidari Majd M, Asgari D, Barar J, Valizadeh H, Kafli V, Abadpour A, et al. Tamoxifen loaded folate acid armed PEGylated magnetic nanoparticles for targeted imaging and therapy of cancer. *Colloids Surf B Biointerfaces* 2013; 106: 117-25. doi:10.1016/j.colsurfb.2013.01.051.

178. Barar J, Omidi Y. Targeted Gene Therapy of Cancer: Second Amendment toward Holistic Therapy. *Bioimpacts* 2013; 3: 49-51. doi:10.5681/bi.2013.014.

179. Khosroushahi AY, Naderi-Manesh H, Yeganeh H, Barar J, Omidi Y. Novel water-soluble polypolyurethane nanocelluloses for cancer chemotherapy: physicochemical characterization and cellular activities. *J Nanobiotechnology* 2012; 10: 2. doi:10.1186/1477-3155-10-2.

180. Omidi Y. Smart multifunctional theranostics: simultaneous diagnosis and therapy of cancer. *Bioimpacts* 2011; 1: 145-7. doi:10.5681/bi.2011.019.

181. Nakhilband A, Barar J, Bidmeshkipour A, Heidari HR, Omidi Y. Bioimpacts of anti epidermal growth factor receptor antisense complexed with polyamidoamine dendrimers in human lung epithelial adenocarcinoma cells. *J Biomed Nanotechnol* 2010; 6: 560-5.

182. Majidi J, Barar J, Baradaran A, Abdolalizadeh J, Omidi Y. Target therapy of cancer: implementation of monoclonal antibodies and nanobodies. *Hum Antibodies 2009*; 18: 81-100. doi:10.3233/HAB-2009-0204.